Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.765663
Primary Topic
CAR-T cell therapy research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Francisco Vega, Kumudha Balakrishnan, Sushanth Gouni, Faezeh Darbaniyan et al.
2 links
bioRxiv (Cold Spring Harbor Laboratory)
CAR-T cell therapy research
preprint

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Francisco Vega, Kumudha Balakrishnan, Sushanth Gouni, Faezeh Darbaniyan, Federico Mario Aletti, Selin Kolsuz, M R Green, Karan L. Chohan, Sridevi Patchva, Sattva Swarup Neelapu, Mario Luiz Marques-Piubelli, Luisa M. Solis Soto, Christopher R. Flowers, Fuliang Chu, Swami Iyer, Jingwei Liu, Wei Lü, Abdur Rehman, Xiaoyun Cheng, C. Le, Jinsheng Weng, Jing Cao, Chun-Yen Lin, Maya Balakumaran, Neeraj Saini, Matthew D. Richard, Yongfu Tang, Kamini Singh, Owhofasa Agbedia
preprint en

Abstract

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

bioRxiv (Cold Spring Harbor Laboratory)
The University of Texas MD Anderson Cancer Center (US)
U.S. Department of Defense, Cancer Prevention and Research Institute of Texas, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, Moonshot Research and Development Program
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon